Intellia Therapeutics
NTLA
NASDAQ
IPO2016
about NTLA
Intellia Therapeutics is a biotechnology company focused on advancing innovative gene-editing therapies using CRISPR-Cas9 technology to develop potential treatments for a wide range of diseases.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $13.73 | $16.76 | $13.21 | $2.75B | 52.27M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.98 | n/a | 106.17 | -772.17% | -710.81% | 0% |